Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652871 · ClinicalTrials.gov registry record · Phase 1
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02652871: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02652871 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02652871, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn about the safety of LY2510924 in combination with cytarabine and idarubicin in patients with relapsed or refractory AML. We will also study if LY2510924 in combination with cytarabine and idarubicin can help to control relapsed or refractory AML. LY2510924 is designed to help cancer cells move from the bone marrow into the bloodstream, where they are exposed to chemotherapy (in this case, cytarabine and idarubicin). This is an investigational study. LY2510924 is not FDA approved or commercially available. Its use in this study is investigational. Cytarabine and idarubicin are approved to treat certain types of leukemia. Their use in this study in combination with LY2510924 is investigational. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG LY2510924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652871
The ClinicalTrials.gov registry entry for NCT02652871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02652871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02652871 about?
NCT02652871 is a clinical study titled "LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia". The goal of this clinical research study is to learn about the safety of LY2510924 in combination with cytarabine and idarubicin in patients with relapsed or refractory AML. We will also study if LY2510924 in combination with cytarabine and idarubicin can help to control relapsed or refractory AML. ...
What is the current status of trial NCT02652871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-05-09. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT02652871?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), LY2510924 (DRUG).
Who is sponsoring clinical trial NCT02652871?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.